The pharmaceutical giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to ...
About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...
The majority are in the very early preclinical stage of development, but applications for regulatory approval have been ...
AN2 Therapeutics , Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on developing treatments for infectious diseases, ...
Chief R&D and commercial officer Najat Khan, PhD, tells GEN Edge the company aims to improve design of studies, accelerate enrollment, and enhance evidence generation.
Pham, Chief Executive Officer, Cadrenal Therapeutics ... therapy as well as other business development opportunities to build the Company’s pipeline, as well as advancing other indications ...
GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...
Johnson & Johnson is contributing $1 million to support the development of curricula and modernization of training and lab ...
Successful launch of sepiapterin would also validate PTC Therapeutics' development capabilities and potentially increase investor confidence in the company's broader pipeline. This could lead to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback